INFLIXIMAB SOTTOCUTE COME TERAPIA DI MANTENIMENTO FUNZIONA DOPO LA INDUZIONE ENDOVENA. LA ANALISI POST-HOC DI DUE TRIAL. DA “Gastroenterology” (FREE)

GASTROENTEROLOGIA, IBD, Senza categoria

Subcutaneous Infliximab (CT-P13 SC) as Maintenance Therapy for Inflammatory Bowel Disease: Two Randomized Phase 3 Trials (LIBERTY) Stephen B Hanauer et al. Abstract Background & aims: CT-P13 subcutaneous (SC), an SC formulation of the intravenous (IV) infliximab biosimilar CT-P13 IV, creates a unique exposure profile. The LIBERTY studies aimed to demonstrate superiority of CT-P13 SC vs…

MODULATORI CENTRALI PER I DISORDINI FUNZIONALI ESOFAGEI. UNA BUONA META-ANALISI ! DOLORE FUNZIONALE TORACICO, GLOBO, DISFAGIA FUNZIONALE….DA “DIGESTIVE & LIVER DISEASE” (FREE)

ENDOSCOPIA, GASTROENTEROLOGIA, MEDICINA INTERNA, Senza categoria

Central neuromodulators for patients with functional esophageal disorders: A systematic review and meta-analysis Jen-Hao Yeh et al. Abstract Backgroud: The use of neuromodulators is prevalent in various functional gastrointestinal disease. However, data concerning the outcomes of these treatments in functional esophageal disorders (FED) remains limited and inadequate. Aims: The aim of the present study is to examine…

OCCHIO GASTROENTEROLOGI! E’ COMPARSO UN OTTIMO ARTICOLO DI FACCIORUSSO & COLL PER CALCOLARE IL SAMPLE SIZE PER IL VOSTRO PROX STUDIO! DA “Expert Review of Gastroenterology & Hepatology”

GASTROENTEROLOGIA, MEDICINA INTERNA, PANCREAS E VIE BILIARI, REAL WORLD EVIDENCE

Principle of sample size calculation in gastroenterology research: a practical guide for clinicians Antonio Facciorusso et al. ABSTRACT Introduction A proper sample size calculation enables to conduct adequately powered randomized controlled trials (RCTs) and to provide a valid assessment of a specific clinical question. Areas covered In the current manuscript, we tried to provide the…

I RISCHI DEL PLACEBO NEI TRIAL CON BIOLOGICI E CON “SMALL MOLECULES” PER LE IBD. UN’IMPORTANTE META-ANALISI. PEGGIORAMENTO DELLA ATTIVITA’ DELLA IBD + 8.5%. NON SARA’ TEMPO DI SOSPENDERE I TRIAL CONTRO PLACEBO NELLE IBD? DA “THE LANCET” (FREE)

GASTROENTEROLOGIA, IBD, METODOLOGIA, Senza categoria

Harms with placebo in trials of biological therapies and small molecules as induction therapy in inflammatory bowel disease: a systematic review and meta-analysis Shahida Din et al. Summary Background Randomised placebo-controlled trials are the gold standard to assess novel drugs in ulcerative colitis and Crohn’s disease. However, there might be risks associated with receiving placebo. We…

UPADACITINIB E’ EFFICACE NEL CROHN PERIANALE CON FISTOLA: UN ANALISI POST-HOC DI 3 TRIAL. RISOLUZIONE DEL DRENAGGIO +47% A 12 SETTIMANE. DA ” Clinical Gastroenterology and Hepatology” (FREE)

CHIRURGIA, GASTROENTEROLOGIA, IBD, METODOLOGIA, Senza categoria

Efficacy and Safety of Upadacitinib for Perianal Fistulizing Crohn’s Disease: A Post Hoc Analysis of 3 Phase 3 Trials Jean-Frédéric Colombel et al. ABSTRACT BACKGROUND & AIMS Efficacy of upadacitinib, an oral Janus kinase inhibitor, for moderate-to-severe Crohn’s disease was demonstrated in phase 3 induction (U-EXCEL, U-EXCEED) and maintenance (U-ENDURE) trials; this post hoc analysis evaluated…

IL TASSO DI RISPOSTA AL PLACEBO NEI TRIAL SULLA MALATTIA DI CROHN. UN’ ATTENTA META-ANALISI SU DATI INDIVIDUALI. NELLA INDUZIONE LA INCIDENZA E’ DEL 27%. ANALISI DEI FATTORI DI RISPOSTA. DA”GASTROENTEROLOGY”

CHIRURGIA, GASTROENTEROLOGIA, IBD, METODOLOGIA, Senza categoria

Placebo rates in Crohn’s disease randomized clinical trials: An individual patient data meta-analysis Virginia Solitano et al. ABSTRACT (260/260) Background & Aims Understanding placebo rates is critical for efficient clinical trial design. We assessed placebo rates and associated factors using individual patient data (IPD) from Crohn’s disease (CD) trials. Methods We conducted a meta-analysis of…